MX2021010050A - Nueva diamino oxidasa recombinante y su uso para el tratamiento de enfermedades caracterizadas por exceso de histamina. - Google Patents

Nueva diamino oxidasa recombinante y su uso para el tratamiento de enfermedades caracterizadas por exceso de histamina.

Info

Publication number
MX2021010050A
MX2021010050A MX2021010050A MX2021010050A MX2021010050A MX 2021010050 A MX2021010050 A MX 2021010050A MX 2021010050 A MX2021010050 A MX 2021010050A MX 2021010050 A MX2021010050 A MX 2021010050A MX 2021010050 A MX2021010050 A MX 2021010050A
Authority
MX
Mexico
Prior art keywords
treatment
dao
histamine
diamine oxidase
glycosaminoglycan
Prior art date
Application number
MX2021010050A
Other languages
English (en)
Inventor
Thomas Böhm
Bernd Jilma
Nicole Borth
Elisabeth Gludovacz
Original Assignee
Univ Wien Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Wien Med filed Critical Univ Wien Med
Publication of MX2021010050A publication Critical patent/MX2021010050A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0014—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4)
    • C12N9/0022—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y104/00—Oxidoreductases acting on the CH-NH2 group of donors (1.4)
    • C12Y104/03—Oxidoreductases acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • C12Y104/03022—Diamine oxidase (1.4.3.22)
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/20—Sequence assembly
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
    • G16B35/10—Design of libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Library & Information Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)

Abstract

La invención se refiere a una diamino oxidasa (DAO) recombinante humada con afinidad de unión a glicosaminoglicano disminuida, en donde dicha DAO comprende al menos una modificación de aminoácido en el dominio de unión de glicosaminoglicano (GAG). La presente invención también se refiere al uso de la DAO en el tratamiento de una afección asociada al exceso de histamina, específicamente en el tratamiento de enfermedades alérgicas crónicas, más específicamente en el tratamiento de anafilaxia, reacción anafiláctica, urticaria crónica, urticaria aguda, asma, fiebre del heno, rinitis alérgica, conjuntivitis alérgica, intoxicación por histamina, dolor de cabeza, dermatitis atópica, enfermedades inflamatorias, mastocitosis, síndrome de activación de mastocitos (MCAS), preeclampsia, hiperemesis gravídica, trabajo de parto prematuro, úlceras pépticas, reflujo ácido, prurito y sepsis.
MX2021010050A 2019-02-19 2020-02-18 Nueva diamino oxidasa recombinante y su uso para el tratamiento de enfermedades caracterizadas por exceso de histamina. MX2021010050A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19157932 2019-02-19
PCT/EP2020/054197 WO2020169577A1 (en) 2019-02-19 2020-02-18 New recombinant diamine oxidase and its use for the treatment of diseases characterized by excess histamine

Publications (1)

Publication Number Publication Date
MX2021010050A true MX2021010050A (es) 2021-09-21

Family

ID=65493995

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021010050A MX2021010050A (es) 2019-02-19 2020-02-18 Nueva diamino oxidasa recombinante y su uso para el tratamiento de enfermedades caracterizadas por exceso de histamina.

Country Status (12)

Country Link
US (1) US20220145269A1 (es)
EP (1) EP3927817A1 (es)
JP (1) JP2022520862A (es)
KR (1) KR20210132650A (es)
AU (1) AU2020225319A1 (es)
BR (1) BR112021015865A2 (es)
CA (1) CA3130751A1 (es)
EA (1) EA202192305A1 (es)
IL (1) IL285452A (es)
MX (1) MX2021010050A (es)
SG (1) SG11202107659SA (es)
WO (1) WO2020169577A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3191387A1 (en) 2020-09-30 2022-04-07 Nobell Foods, Inc. Recombinant milk proteins and food compositions comprising the same
US10894812B1 (en) 2020-09-30 2021-01-19 Alpine Roads, Inc. Recombinant milk proteins
US10947552B1 (en) 2020-09-30 2021-03-16 Alpine Roads, Inc. Recombinant fusion proteins for producing milk proteins in plants
WO2023235897A2 (en) * 2022-06-03 2023-12-07 Oyster Point Pharma. Inc. Aav vector encoding diamine oxidase and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1317067B1 (it) 2000-11-29 2003-05-26 Univ Roma Istaminasi di origine vegetale nel trattamento dello shock allergico esettico e nell'asma allergico.
AT502098B8 (de) 2004-07-07 2007-06-15 Albert Dr Missbichler Diaminooxidase-hältige zusammensetzung
PL2611454T3 (pl) 2010-09-02 2015-09-30 Naturland Magyarorszag Termelo Es Kereskedelmi Kft Doustny preparat zawierający histaminazę pochodzenia roślinnego, oporną na pepsynę i trypsynę oraz sposób jego wytwarzania

Also Published As

Publication number Publication date
KR20210132650A (ko) 2021-11-04
BR112021015865A2 (pt) 2021-10-05
US20220145269A1 (en) 2022-05-12
EA202192305A1 (ru) 2021-12-08
CA3130751A1 (en) 2020-08-27
CN113785052A (zh) 2021-12-10
IL285452A (en) 2021-09-30
WO2020169577A1 (en) 2020-08-27
EP3927817A1 (en) 2021-12-29
AU2020225319A1 (en) 2021-10-14
SG11202107659SA (en) 2021-09-29
JP2022520862A (ja) 2022-04-01

Similar Documents

Publication Publication Date Title
MX2021010050A (es) Nueva diamino oxidasa recombinante y su uso para el tratamiento de enfermedades caracterizadas por exceso de histamina.
EA201290413A1 (ru) МУТИРОВАННЫЕ Fc АНТИТЕЛ С УСТРАНЕННЫМИ ЭФФЕКТОРНЫМИ ФУНКЦИЯМИ
IN2012DN03817A (es)
MX2017013113A (es) Anticuerpos anti-pacap y sus usos.
AR093183A1 (es) Aumento de la potencia de celulas madre de placenta usando moleculas de arn moduladoras
MX2019006835A (es) Uso de anticuerpos anti-cgrp o anti-cgrp-r o fragmentos de anticuerpo para tratar o prevenir formas cronicas y agudas de diarrea.
NO20081615L (no) Fremgangsmater for a forbedre avvanningsevnen til slam med a-amylasebehandling
EA201791984A1 (ru) Способы уменьшения уровня fc-содержащих агентов в сыворотке с применением fcrn-антагонистов
WO2010038086A8 (en) P38 map kinase inhibitors
WO2011141823A3 (en) Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
WO2006003388A8 (en) Compositions and methods for treating inflammatory disorders
NO20091326L (no) Indazolderivater som modulatorer av interleukin-1-reseptor-assosiert kinase
NO20074943L (no) Roflumilast for behandlingen av diabetes mellitus
WO2005101838A3 (en) Piperazinylpiperidine derivatives as chemokine receptor antagonists
WO2010065850A3 (en) Interleukin 6 and tumor necrosis factor alpha as biomarkers of jnk inhibition
ATE544463T1 (de) Verwendung von scf und g-scf bei der behandlung von hirnischämie und neurologischen störungen
EP4272829A3 (en) Peptide having effects of increasing telomerase activity and extending telomere, and composition containing same
WO2017006052A3 (fr) UTILISATION DE FRAGMENTS Fc MODIFIÉS EN IMMUNOTHÉRAPIE
WO2014079545A8 (en) Thioether derivatives as protein kinase inhibitors
WO2017208174A3 (en) Methods of treating disease with pfkfb3 inhibitors
EA201890893A1 (ru) Способы лечения повреждений или состояний, относящихся к отеку цнс
WO2012142367A3 (en) Compositions and methods for treatment of pulmonary diseases and conditions
MX2018013812A (es) Compuestos moduladores del receptor adrenérgico y sus métodos de uso.
WO2008008487A3 (en) Gene expression profiling for identification, monitoring and treatment of multiple sclerosis
WO2013172872A8 (en) Pyrimidine diamine derivatives as inhibitors of cytosolic hsp90